Subdued Growth No Barrier To Ascendis Pharma A/S' (NASDAQ:ASND) Price

Ascendis Pharma A/S' (NASDAQ:ASND) price-to-sales (or "P/S") ratio of 22.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where around half

Simply Wall StJul 18 14:05 ET

$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 43.24% on an annualized basis producing an average annual return of 54.04%. Currently, Ascendis Pharma has a

BenzingaJul 18 13:00 ET

European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday

European equities traded in the US as American depositary receipts were moving moderately lower late Thursday morning, declining 0.72% to 1,423.26 on the S&P Europe Select ADR Index.From continental

MT NewswiresJul 18 11:08 ET

Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $260

Wells Fargo analyst Derek Archila maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and adjusts the target price from $262 to $260.According to TipRanks data, the analyst has a success

Moomoo NewsJul 11 07:31 ET · Ratings

The Small-Cap Stock Boom Is Overdue. This Fund Is Ready.

"I can't tell you we are at the absolute bottom," says Harbor Small Cap Growth fund manager William Muggia. "But it sure smells like it."

BarronsJul 10 02:30 ET

Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada

Ascendis Pharma (ASND) and Pendopharm have signed a distribution agreement under which the latter will oversee regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment Trans

MT NewswiresJul 5 09:58 ET